Methodological Issues in Clinical Drug Development for Essential Tremor
- Methodological Issues in Clinical Drug Development for Essential Tremor
- Carranza, Michael A.
Snyder, Madeline R.
Elble, Rodger J.
Boutzoukas, Angelique E.
Zesiewicz, Theresa A.
- Center for Parkinson's Disease and Other Movement Disorders
- Persistent URL:
- Book/Journal Title:
- Tremor and Other Hyperkinetic Movements
- Essential tremor (ET) is one of the most common tremor disorders in the world. Despite this, only two medications have received Level A recommendations from the American Academy of Neurology to treat it (primidone and propranolol). Even though these medications provide relief to a large group of ET patients, up to 50% of patients are non-responders. Additional medications to treat ET are needed. This review discusses some of the methodological issues that should be addressed for quality clinical drug development in ET.
- Item views
text | xml
- Suggested Citation:
- Michael A. Carranza, Madeline R. Snyder, Rodger J. Elble, Angelique E. Boutzoukas, Theresa A. Zesiewicz, 2012, Methodological Issues in Clinical Drug Development for Essential Tremor, Columbia University Academic Commons, https://doi.org/10.7916/D80Z7D09.